US20130197089A1 - Compositions for the treatment of actinic keratosis - Google Patents

Compositions for the treatment of actinic keratosis Download PDF

Info

Publication number
US20130197089A1
US20130197089A1 US13/753,783 US201313753783A US2013197089A1 US 20130197089 A1 US20130197089 A1 US 20130197089A1 US 201313753783 A US201313753783 A US 201313753783A US 2013197089 A1 US2013197089 A1 US 2013197089A1
Authority
US
United States
Prior art keywords
ibuprofen
treatment
topical formulation
weight
lesions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/753,783
Other languages
English (en)
Inventor
Juergen Warnecke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dolorgiet GmbH and Co KG
Original Assignee
Dolorgiet GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dolorgiet GmbH and Co KG filed Critical Dolorgiet GmbH and Co KG
Assigned to DOLORGIET GMBH & CO. KG reassignment DOLORGIET GMBH & CO. KG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WARNECKE, JUERGEN, DR.
Publication of US20130197089A1 publication Critical patent/US20130197089A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations

Definitions

  • the total number of lesions in the ibuprofen group changed from 18 at the beginning of the treatment to 3.7 at the end of the 90 days of treatment time.
  • the diclofenac group there were 36.8 lesions at the start, which changed to an average of 19.2 lesions towards the end of the treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
US13/753,783 2012-01-30 2013-01-30 Compositions for the treatment of actinic keratosis Abandoned US20130197089A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12153082.8 2012-01-30
EP12153082 2012-01-30

Publications (1)

Publication Number Publication Date
US20130197089A1 true US20130197089A1 (en) 2013-08-01

Family

ID=47563324

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/753,783 Abandoned US20130197089A1 (en) 2012-01-30 2013-01-30 Compositions for the treatment of actinic keratosis

Country Status (4)

Country Link
US (1) US20130197089A1 (fr)
EP (1) EP2620146A1 (fr)
AU (1) AU2013200466A1 (fr)
NZ (1) NZ606177A (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017008831A1 (fr) * 2015-07-10 2017-01-19 Infectopharm Arzneimittel Und Consilium Gmbh Utilisation d'hydroxyde de potassium dans le traitement de la kératose actinique
WO2018165647A1 (fr) * 2017-03-10 2018-09-13 Athenex, Inc. Méthodes de traitement et/ou de prévention de la kératose actinique
RU2805929C2 (ru) * 2017-03-10 2023-10-24 АйТиЭнЭкс ЭсПиВи, ЭлЭлСи Способы лечения и/или предотвращения актинического кератоза

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3213744A1 (fr) * 2016-03-01 2017-09-06 Chemische Fabrik Kreussler & Co. Gmbh Preparation galenique de nsaid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053290A1 (en) * 2006-03-08 2009-02-26 Sand Bruce J Transdermal drug delivery compositions and topical compositions for application on the skin
US20090123504A1 (en) * 2007-11-12 2009-05-14 Kimberly-Clark Worldwide, Inc. Olive oil formulation for pain relief

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3532562A1 (de) * 1985-09-12 1987-03-12 Dolorgiet Gmbh & Co Kg Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US20050137164A1 (en) * 2003-09-22 2005-06-23 Moshe Arkin Diclofenac compositions for the treatment of skin disorders
EP2143421A1 (fr) * 2008-07-07 2010-01-13 Almirall Hermal GmbH Composition topique pour le traitement de la kératose actinique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053290A1 (en) * 2006-03-08 2009-02-26 Sand Bruce J Transdermal drug delivery compositions and topical compositions for application on the skin
US20090123504A1 (en) * 2007-11-12 2009-05-14 Kimberly-Clark Worldwide, Inc. Olive oil formulation for pain relief

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017008831A1 (fr) * 2015-07-10 2017-01-19 Infectopharm Arzneimittel Und Consilium Gmbh Utilisation d'hydroxyde de potassium dans le traitement de la kératose actinique
RU2706234C2 (ru) * 2015-07-10 2019-11-15 Инфектофарм Арцнаймиттель Унд Консилиум Гмбх Применение гидроксида калия при лечении актинического кератоза
AU2015402192B2 (en) * 2015-07-10 2021-06-10 Infectopharm Arzneimittel Und Consilium Gmbh Use of potassium hydroxide in the treatment of actinic keratosis
US11045494B2 (en) 2015-07-10 2021-06-29 Infectopharm Arzneimittel Und Consilium Gmbh Use of potassium hydroxide in the treatment of actinic keratosis
WO2018165647A1 (fr) * 2017-03-10 2018-09-13 Athenex, Inc. Méthodes de traitement et/ou de prévention de la kératose actinique
US10617693B2 (en) 2017-03-10 2020-04-14 Athenex, Inc. Methods of treating and/or preventing actinic keratosis
US11497750B2 (en) 2017-03-10 2022-11-15 Atnx Spv, Llc Methods of treating and/or preventing actinic keratosis
RU2805929C2 (ru) * 2017-03-10 2023-10-24 АйТиЭнЭкс ЭсПиВи, ЭлЭлСи Способы лечения и/или предотвращения актинического кератоза

Also Published As

Publication number Publication date
EP2620146A1 (fr) 2013-07-31
NZ606177A (en) 2014-03-28
AU2013200466A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
JP6185536B2 (ja) ブリモニジンゲル組成物及び使用方法
US20150011490A1 (en) Treatment of papulopustular rosacea with ivermectin
JP5747392B2 (ja) 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物
US20050137164A1 (en) Diclofenac compositions for the treatment of skin disorders
US20110281947A1 (en) Methods of administering diclofenac compositions for treating photodamaged skin
IL269182B1 (en) Methods for the treatment and/or prevention of actinic radiation
JP2013540142A (ja) 局所ゲル組成物
JP2016196419A (ja) 皮膚外用製剤
US20130197089A1 (en) Compositions for the treatment of actinic keratosis
WO1999012545A2 (fr) Medicaments contenant acyclovir
EP0484112A2 (fr) Utilisation du lithium dans le traitement ou la prophylaxie du Molluscum contagiosum
US20110159106A1 (en) Dermatological compositions containing an association of peroxidized lipids and zinc, and uses thereof in particular in the treatment of herpes
KR20110138709A (ko) 5-아미노레불린산 또는 이의 에스테르를 포함하는 여드름 개선용 조성물
US20170119703A1 (en) Methods of treatment of acne vulgaris using topical dapsone compositions
US9669045B2 (en) Treatments for actinic keratoses
US20230157979A1 (en) Topical diclofenac compositions and methods
RU2805929C2 (ru) Способы лечения и/или предотвращения актинического кератоза
US20160263065A1 (en) Topical pharmaceutical gel composition of diclofenac sodium
EP4081540A1 (fr) Cyclosporine topique pour le traitement du psoriasis et d'autres maladies
CN118121532A (zh) 一种含有曲法罗汀的药物组合物及其应用
IL272322B2 (en) The compositions for use in the Jericho rose treatment
US20160106723A1 (en) Methods to sense and treat subclinical skin damage
US20130196942A1 (en) Composition for Skin Treatment
JP2018519276A (ja) 日光角化症の治療における水酸化カリウムの使用
US20160199326A1 (en) Use of trifluoroacetic acid as keratolytic agent to treat hyperkeratotic skin lesions

Legal Events

Date Code Title Description
AS Assignment

Owner name: DOLORGIET GMBH & CO. KG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WARNECKE, JUERGEN, DR.;REEL/FRAME:030533/0590

Effective date: 20130427

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION